Skip to main content
      RT @RHEUMarampa: Tofa for RA by the grp of Dr. Atul Deodhar:
      >Tofa(56%) vs. pbo(29.4%)-significant improvement in AS

      sheila RHEUMarampa

      3 years 7 months ago
      Tofa for RA by the grp of Dr. Atul Deodhar: >Tofa(56%) vs. pbo(29.4%)-significant improvement in ASAS20 at wk 16 >Primary & secondary endpts met >No new safety signals reported @Rheumnow #ACR20 https://t.co/G9U5cCQU7K
      RT @MeralElRamahiMD: Poll results are in! 76% of you take into account the location of bone marrow edema in the SI joint

      Meral K. El Ramahi, MD MeralElRamahiMD

      3 years 7 months ago
      Poll results are in! 76% of you take into account the location of bone marrow edema in the SI joint of patients with inflammatory back pain in trying to determine if a patient has SpA! #ACR20 @RheumNow https://t.co/gwySNvfSH5
      A Review of RA Studies at ACR: Dr. Janet Pope

      Dr. Janet Pope reviews #0483, #0187, #1715, #0151 and #1736 presented at the 2020 ACR annual meeting.

      Lifestyle and Risk of RA, Lupus: Dr. Janet Pope

      Dr. Janet Pope reviews abstracts #1198 and #1473 presented at the 2020 ACR annual meeting.

      RT @SituationRheum: 📌 #ACR20 Checkpoint Inhibitors: Past, Present and Future

      👉close surveillance ➡️ early det

      Elizabeth Graef SituationRheum

      3 years 7 months ago
      📌 #ACR20 Checkpoint Inhibitors: Past, Present and Future 👉close surveillance ➡️ early detection of iRAEs➡️ early treatment➡️ reversibility or ⬇️severity #ACRAmbassador https://t.co/AM2mfYmAtI
      RT @SituationRheum: And we're off! #ACR20 year in review

      ⭐️@philseo's #Vasculitis lecture⭐️

      Take home lessons/

      Elizabeth Graef SituationRheum

      3 years 7 months ago
      And we're off! #ACR20 year in review ⭐️@philseo's #Vasculitis lecture⭐️ Take home lessons/ remaining questions from GiACTA ⬇️ #ACRambassador https://t.co/7C9QxbUeNH
      RT @SituationRheum: 📌More #Vasculitis pearls from #ACR20 Year in Review

      #PEXIVAS in a nutshell ⬇️

      #ACRambassa

      Elizabeth Graef SituationRheum

      3 years 7 months ago
      📌More #Vasculitis pearls from #ACR20 Year in Review #PEXIVAS in a nutshell ⬇️ #ACRambassador https://t.co/PnoP7QIiYs
      RT @DrBhana: from #ACR20 Dr. Abbey Abelson. There was reduction in hip fractures in the US until there was drop in reim

      Suleman Bhana, MD DrBhana

      3 years 7 months ago
      from #ACR20 Dr. Abbey Abelson. There was reduction in hip fractures in the US until there was drop in reimbursement for DEXA/Bone Density. @ACRheum has been advocating on Capitol Hill to restore reimbursement. Bad policy harms, but good policy can save lives. #ACRambassador https://t.co/ARo762Vozp
      RT @vksandhumd: Thank you Prof Laure Gossec for discussing recent data in Psoriatic Arthritis #ACR20 #ACRambassador http

      Vaneet K Sandhu, MD vksandhumd

      3 years 7 months ago
      Thank you Prof Laure Gossec for discussing recent data in Psoriatic Arthritis #ACR20 #ACRambassador https://t.co/f0o8m5K0d2 https://t.co/Wm0sQDUeY1
      RT @BharatKumarMD: Some behind the scenes action at #ACR20 #ACRKnowledgeBowl!! More to come tomorrow at 1pm EST with fi

      Bharat Kumar BharatKumarMD

      3 years 7 months ago
      Some behind the scenes action at #ACR20 #ACRKnowledgeBowl!! More to come tomorrow at 1pm EST with finals! https://t.co/3yLgqqC0Yy
      RT @vksandhumd: ARCH study -- n~4100
      Romo vs Alendronate x 12 mo
      Alendronate 12-24 mo
      RRR 38% https://t.co/d0G7x4TqUT

      Vaneet K Sandhu, MD vksandhumd

      3 years 7 months ago
      ARCH study -- n~4100 Romo vs Alendronate x 12 mo Alendronate 12-24 mo RRR 38% https://t.co/d0G7x4TqUT
      RT @vksandhumd: Hypophosphatasia
      - CPPD/chondrocal, enthesop'y, DISH, exostoses
      - DDx of Low ALP: milk-alkali, Vit D int

      Vaneet K Sandhu, MD vksandhumd

      3 years 7 months ago
      Hypophosphatasia - CPPD/chondrocal, enthesop'y, DISH, exostoses - DDx of Low ALP: milk-alkali, Vit D intoxic'n, Wilson dz, via C def, celiac dz, adyn renal osteodystrophy, Cushing dz, hypothyroid, major sx, MM Rx - asfotase alpha- bone targeted replac't Rx #ACR20 #ACRambassador https://t.co/FJ1355MdKG
      RT @SattuiSEMD: #ACR20 Abstracts on #ILD
      Rituximab in ILD (all observational)
      #1053 ➡️ 47 with CTD-ILD: overall imp

      Sebastian E. Sattui MD, MS SattuiSEMD

      3 years 7 months ago
      #ACR20 Abstracts on #ILD Rituximab in ILD (all observational) #1053 ➡️ 47 with CTD-ILD: overall improvement or stability at 36m #1051 ➡️ 50 with IPAF: >70% stable or improved at 12m #1047 ➡️ 47 patients CTD-ILD or IPAF: good experience with MMF and RTX #ACRambassador https://t.co/klfVwIH5b6